Showing results (41-50 of 66) with videos related to
Sort By:
Pageof 7
Breast Cancer Research and Treatment|January 29, 2016
Discordant assessment of tumor biomarkers by histopathological and molecular assays in the EORTC randomized controlled 10041/BIG 03-04 MINDACT trial breast cancer : Intratumoral heterogeneity and DCIS or normal tissue components are unlikely to be the cause of discordanceGiuseppe Viale, Leen Slaets, Femke A de Snoo, et al.European Journal of Cancer (Oxford, England : 1990)|November 5, 2011
The EORTC 10041/BIG 03-04 MINDACT trial is feasible: results of the pilot phaseEmiel Rutgers, Martine J Piccart-Gebhart, Jan Bogaerts, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 13, 2019
RECIST 1.1 for Response Evaluation Apply Not Only to Chemotherapy-Treated Patients But Also to Targeted Cancer Agents: A Pooled Database AnalysisSaskia Litière, Gaëlle Isaac, Elisabeth G E De Vries, et al.European Journal of Cancer (Oxford, England : 1990)|May 18, 2010
Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI)Patrick Schöffski, Jean-Yves Blay, Jacques De Greve, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 30, 2009
Role of axillary clearance after a tumor-positive sentinel node in the administration of adjuvant therapy in early breast cancerMarieke E Straver, Philip Meijnen, Geertjan van Tienhoven, et al.Nature Medicine|January 6, 2009
A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancerPierre Farmer, Hervé Bonnefoi, Pascale Anderle, et al.Annals of Surgical Oncology|March 20, 2010
Sentinel node identification rate and nodal involvement in the EORTC 10981-22023 AMAROS trialMarieke E Straver, Philip Meijnen, Geertjan van Tienhoven, et al.The Lancet. Oncology|May 17, 2011
TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trialHervé Bonnefoi, Martine Piccart, Jan Bogaerts, et al.JCO Precision Oncology|April 18, 2024
Tumor Size Is Not Everything: Advancing Radiomics as a Precision Medicine Biomarker in Oncology Drug Development and Clinical Care. A Report of a Multidisciplinary Workshop Coordinated by the RECIST Working GroupErica C Nakajima, Amber Simpson, Jan Bogaerts, et al.Journal of the National Cancer Institute|September 7, 2006
Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancerMarc Buyse, Sherene Loi, Laura van't Veer, et al.Pageof 7